HAEMATOLOGY
in Washington DC. Should you wish to find out more about this multi-centre evaluation, please visit the Sysmex- sponsored Product Theatre session, Tuesday, 24 June, 13:30 EDT, where study lead Sean Platton will provide an overview of the key study results. Recently, Sean Platton presented a subset of the study data at the International Society for Laboratory Haematology (ISLH) International Symposium on Technical Innovations in Laboratory Haematology conference, held during May in Halifax, Nova Scotia, Canada. This data highlights the success of multi-site collaboration in determining agonist-specific reference ranges, of which guidelines3
recommend a minimum
of 40 samples, and this is often difficult for single laboratories to obtain. The AUTOPLATE study group collectively achieved a dataset of 234 healthy normal donor samples to calculate the normal reference range.
AUTOPLATE study group lead Sean Platton, pictured at the ISLH’s International Symposium on Technical Innovations in Laboratory Haematology conference, held May 2025 in Halifax, Nova Scotia, Canada, where he presented a subset of the study data.
patient’s healthcare journey. Sean Platton, the AUTOPLATE study group lead said the following: “The objective of this project from day one was to be able to support laboratories across the UK and further afield with data that supports the implementation of new LTA technology in platelet function disorder investigations and to also support accreditation purposes. Within the study group alone, single centres had only normal patient samples during the study period, demonstrating the difficulty of obtaining a range of platelet function disorder pathologies for verification purposes. The receptiveness of each laboratory to collaborate facilitated an efficient data collection process with a range of platelet function disorders, with the result being a comprehensive dataset.”
This network now extends above and beyond the initial study, primarily to support knowledge and expertise sharing within the National Health Service in the UK.
In addition to the active sharing of data, the new automated LTA platform has opened opportunities for research evaluations within platelet function disorders. The walkaway technology, with a time for result of less than 15 minutes for a standard 11-agonist panel, facilitates a higher volume of samples to be processed with less manual intervention required compared to semi-automated LTA platforms, which has contributed to the comprehensive dataset achieved by the AUTOPLATE study group without significant resource investment. The
34
new automated LTA platform also has a significantly reduced PRP volume requirement compared to semi- automated LTA platforms, which means no additional samples were required from patients, and thus the research could be performed in conjunction with the routine screening for platelet function disorders and with no additional patient burden.
Helping other laboratories For any haemophilia centre considering the implementation of integrated LTA on the CN-series, this comprehensive dataset can provide the foundation of their internal verification as supplementary evidence to the locally collected dataset, overcoming the barrier of limited sample availability. This data will also help clinicians to understand the next-generation platforms being released to markets, and the impact of innovative technologies on patient care, turnaround times, and laboratory resource requirements. In addition to directly providing data, the AUTOPLATE study group forms a foundation network willing to support other laboratories across Europe with expertise on the new LTA platform.
Presenting the data The AUTOPLATE study group is currently in the process of writing up the study data for publication, as a result of which several poster and oral presentations will be given at the International Society for Thrombosis and Haemostasis (ISTH) meeting, taking place 21-25 June, 2025,
References 1 Born GV. Aggregation of blood platelets
by adenosine diphosphate and its reversal. Nature. 1962;194:927-929. doi:10.1038/194927b0
2 O’Brien JR. The adhesiveness of native platelets and its prevention. J Clin Pathol. 1961;14(2):140-149. doi:10.1136/ jcp.14.2.140
3 Gomez K, Anderson J, Baker P, et al. Clinical and laboratory diagnosis of heritable platelet disorders in adults and children: a British Society for Haematology Guideline. Br J Haematol. 2021;195(1):46- 72. doi:10.1111/bjh.17690
4 CLSI. Platelet Function Testing by Aggregometry, 1st edn, CLSI guideline H58-A. Clinical and Laboratory Standards Institute; 2008.
5 Oved JH, Lambert MP, Kowalska MA, Poncz M, Karczewski KJ. Population based frequency of naturally occurring loss-of- function variants in genes associated with platelet disorders. J Thromb Haemost. 2021;19(1):248-254. doi:10.1111/jth.15113
6 United Kingdom Haemophilia Centres Doctors Organisation. UKHCDO 2024 annual report. (UKHCDO; 2024) www.
ukhcdo.org/home-2/annual-reports/
George Tarpley is the Haemostasis Product Marketing Manager at Sysmex UK and supported the project management of the AUTOPLATE study group. George has research interests in haemostasis pre- analytics and platelet factor 4 disorders and has presented his data at national and international conferences.
0333 320 3460
info@sysmex.co.uk www.sysmex.co.uk
JUNE 2025
WWW.PATHOLOGYINPRACTICE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
